As Hugh Fatodu, RPh, MBA, cites the Orphan Drug Act of 1983 and explains how the act has incentivized pharmaceutical companies to expand on research and continue to develop a variety of orphan drugs for the treatment of rare diseases, the panelists explore the evolving orphan drug market and discuss their concerns.
Mr Fatodu explains that earlier-approved orphan drug products are now being used beyond their original indications and states that he is concerned about the quality of the data that is being reviewed to support product usage. He believes that this factor may affect patient exclusivity and drug pricing.
Maria Lopes, MD, MS, and Michelle Petri, MD, MPH, further discuss rising drug costs for newly developed agents and explain how expensive pricing affects a clinician’s choice to administer an appropriate drug to a patient.
The panelists conclude their discussion by reviewing cost versus quality perceptions as the US transitions into a new delivery model of care.
CMS' 340B Repayment Proposal May Harm Vulnerable Hospitals, Reward Those With Higher Revenues
April 26th 2024The 340B hospitals not receiving an offsetting lump-sum payment from CMS following 2018-2022 cuts later ruled unlawful are disproportionately rural, publicly owned, and nonacademic, according to a new study.
Read More
Examining Low-Value Cancer Care Trends Amidst the COVID-19 Pandemic
April 25th 2024On this episode of Managed Care Cast, we're talking with the authors of a study published in the April 2024 issue of The American Journal of Managed Care® about their findings on the rates of low-value cancer care services throughout the COVID-19 pandemic.
Listen
Navigating Health Policy in an Election Year: Insights From Dr Dennis Scanlon
April 2nd 2024On this episode of Managed Care Cast, we're talking with Dennis Scanlon, PhD, the editor in chief of The American Journal of Accountable Care®, about prior authorization, price transparency, the impact of health policy on the upcoming election, and more.
Listen
Mental Health Diagnoses, Care Challenges Rise Among US Youth, Report Finds
April 26th 2024While behavioral health care utilization has been rising, the treatment landscape has been worsening. New findings show that 20% of youths did not receive any form of treatment within 3 months of their initial behavioral health diagnosis.
Read More